Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Hillel Panitch, Douglas Goodin, Gordon Francis, Peter Chang, Patricia Coyle, Paul O'Connor, David Li, Brian Weinshenker

Research output: Contribution to journalArticle

78 Scopus citations


The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing-remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44 mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30 mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalJournal of the neurological sciences
Issue number1
StatePublished - Dec 15 2005



  • Comparative study
  • Interferon beta
  • Magnetic resonance imaging (MRI)
  • Multiple sclerosis (MS)
  • Neutralizing antibodies

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this